Lords Mark Industries Completes Phase I Expansion Ahead of Schedule

Lords Mark Industries Limited has announced the successful completion of Phase I of its expansion at the Silvassa facility, nearly three months ahead of its December 2026 target. This expansion increases their surgical and orthopaedic product portfolio from 36 to 54 SKUs. The new production line is set to commence commercial operations on October 11, 2026. The company's existing 36 products have US FDA approval, and the 18 new SKUs are expected to receive clearance before December 2026. This strategic move enhances manufacturing capabilities, expands market reach, and supports the company's global ambitions in the medical devices sector.